| Shauna Dallas Ford, PHARMD | |
|
3965 Crosshaven Dr, Vestavia, AL 35243-5417 | |
| (205) 969-0767 | |
| Not Available |
| Full Name | Shauna Dallas Ford |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 3965 Crosshaven Dr, Vestavia, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235571118 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 17461 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shauna Dallas Ford, PHARMD 3965 Crosshaven Dr, Vestavia, AL 35243-5417 Ph: (205) 969-0767 | Shauna Dallas Ford, PHARMD 3965 Crosshaven Dr, Vestavia, AL 35243-5417 Ph: (205) 969-0767 |
News Archive
An international team of scientists, including researchers at Columbia University Medical Center, has identified a key metabolic enzyme that common malaria parasites require for survival at each stage of infection in humans. The findings raise the possibility of a new approach to combating malaria, one of the world's deadliest diseases. The study was published today in the online edition of the journal Nature.
Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.
Canadian lung cancer patients are likely to suffer significant stigma due to the disease's link to smoking, a connection that may impact the care and treatment patients receive. According to a 16-country survey carried out by Ipsos MORI on behalf of The Global Lung Cancer Coalition, one in five Canadians admit feeling less sympathetic towards lung cancer sufferers because of its known association with smoking cigarettes and other tobacco products.
Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, announced today that the company has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Symbiq 3.13 infusion device, the enhanced version of the company's advanced infusion system platform.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
› Verified 6 days ago
Dr. Macie Lynn Sobers, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 737 Montgomery Hwy, Vestavia, AL 35216 Phone: 205-823-5442 Fax: 205-823-5853 | |
Mr. James Kevin Langston, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1745 Cedarwood Rd, Vestavia, AL 35216 Phone: 205-930-7004 Fax: 205-930-7410 | |
Dr. Kelley Crawford Brown, DOCTOR OF PHARMACY Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2004 Southwood Rd, Vestavia, AL 35216 Phone: 931-625-4568 | |
Tamara Renfrow, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4197 Crosshaven Dr, Vestavia, AL 35243 Phone: 205-967-4951 | |
Kelsey Knorr, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 Vestavia Pkwy Ste 2300, Vestavia, AL 35216 Phone: 866-607-3561 | |
Ronda Lacey, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4168 River View Cv, Vestavia, AL 35243 Phone: 205-305-2022 | |
Dr. Tyler Derrick, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3201 Endeavor Ln, Vestavia, AL 35242 Phone: 205-421-2983 |